DEXMEDETOMIDINE HYDROCHLORIDE INJECTION SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE)

Prieinama:

OMEGA LABORATORIES LIMITED

ATC kodas:

N05CM18

INN (Tarptautinis Pavadinimas):

DEXMEDETOMIDINE

Dozė:

400MCG

Vaisto forma:

SOLUTION

Sudėtis:

DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) 400MCG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Produkto santrauka:

Active ingredient group (AIG) number: 0152679004; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2023-07-11

Prekės savybės

_Dexmedetomidine Hydrochloride Injection _
_Page 1 of 34 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
DEXMEDETOMIDINE HYDROCHLORIDE INJECTION
Solution, 4 mcg/mL dexmedetomidine (as dexmedetomidine hydrochloride),
intravenous infusion
(Ready to use, 50 mL and 100 mL vials)
Alpha2-adrenergic agonist
Omega Laboratories Limited
11177 Hamon Street
Montreal, Canada
H3M 3E4
Submission Control Number: 280635
Date
of
Initial
Authorization:
JUL 11, 2023
Date
of
Revision:
NOV
27, 2023
_Dexmedetomidine Hydrochloride Injection _
_Page 2 of 34 _
RECENT MAJOR LABEL CHANGES
4.1 Dosing Considerations
11/2023
7.0 Warnings and Precautions
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
...........................................................................................................................
4
1.1
Pediatrics
.................................................................................................................................
4
1.2
Geriatrics
.................................................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................................
4
4.1
Dosing Considerations
.............................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
....